Open AccessA phase I/II study of bexarotene with carboplatin and weekly paclitaxel for the treatment of patients with advanced non-small cell lung cancer
Author(s) -
Konstantin H. Dragnev,
Jeremy D. Whyman,
Cynthia K. Hahn,
Peter E. Kebbekus,
Sarah F. Kokko,
Sunil Bhatt,
James R. Rigas
Publication year - 2018
Publication title -
journal of thoracic disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.682
H-Index - 60
eISSN - 2077-6624
pISSN - 2072-1439
DOI - 10.21037/jtd.2018.09.10
Subject(s) - bexarotene , carboplatin , medicine , lung cancer , paclitaxel , neutropenia , tolerability , gastroenterology , chemotherapy , pharmacology , oncology , surgery , adverse effect , cisplatin , biochemistry , chemistry , nuclear receptor , transcription factor , gene
Rexinoids demonstrate anti-proliferative differentiation-inducing activity in multiple cancer types, including NSCLC. Prior studies have shown promising results when combining rexinoids with chemotherapy. This phase I/II study evaluates the tolerability and activity of a rexinoid, bexarotene, combined with weekly paclitaxel and monthly carboplatin.